2017 Annual General Meeting - Chairman's Address to Shareholders

Thursday, 2 November 2017

A year of excellent progress

We are pleased to report that during the financial year we achieved significant licensing, clinical, intellectual property and commercial milestones that position the company to unlock significant value in the business over the next 12 months.